Products for Research Use Only

HTH-02-006

CAT: 0804-HY-156397-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-156397-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
HTH-02-006 is a NUAK2 inhibitor, with an IC50 value of 126 nM. HTH-02-006 inhibits NUAK2-mediated signaling by reducing phosphorylation of its substrate MYPT1 at S445 and downstream MLC. HTH-02-006 shows growth inhibitory efficacy in YAP-high cancer cells (HuCCT-1, SNU475) . HTH-02-006 significantly suppresses YAP-induced hepatomegaly (reduced liver/body weight ratio) in TetO-YAP S127A transgenic mice and demonstrates significant anti-tumor efficacy in mice bearing HMVP2 prostate cancer allografts. HTH-02-006 can be used for the study of liver cancer and prostate cancer[1][2].
UNSPSC
12352005
Target
AMPK; YAP
Type
Reference compound
Related Pathways
Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hth-02-006.html
Purity
99.42
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CCC(NC1=CC=CC(OC2=NC(NC3=CC=C(C=C3OC)N4CCN(CC4)C)=NC=C2I)=C1)=O
Molecular Formula
C25H29IN6O3
Molecular Weight
588.44
References & Citations
[1]Yuan WC, et al. NUAK2 is a critical YAP target in liver cancer. Nat Commun. 2018 Nov 16;9 (1) :4834.|[2]Fu W, et al. NUAK family kinase 2 is a novel therapeutic target for prostate cancer. Mol Carcinog. 2022 Mar;61 (3) :334-345.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NUAK2